Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 01, 2015 2:22 PM ET


Company Overview of Hemobiotech, Inc.

Company Overview

Hemobiotech, Inc., a biopharmaceutical company, provides research and development of human blood substitute technology licensed from Texas Tech University Health Service Center in Texas. It focuses primarily on the development of HemoTech, an oxygen-carrying solution that performs like red blood cells. The company was incorporated in 2003 and is headquartered in Dallas, Texas.

5001 Spring Valley Road

Suite 1040 - West

Dallas, TX 75244

United States

Founded in 2003

4 Employees





Key Executives for Hemobiotech, Inc.

Interim Chief Executive Officer, Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee
Age: 75
Founder and Vice Chairman
Age: 47
Interim Chief Financial Officer, Secretary, Director, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee
Age: 82
Chief Medical Officer
Age: 88
Acting Vice President, Principal Investigator of Research & Development and Advisor
Age: 63
Compensation as of Fiscal Year 2015.

Hemobiotech, Inc. Key Developments

SEC Revokes Registration Of Registered Securities Of HemoBioTech

An Administrative Law Judge has issued an initial decision of default as to HemoBioTech, Inc. The Order Instituting Proceedings alleged that the company repeatedly failed to file timely periodic reports while its securities were registered with the Securities and Exchange Commission (SEC or the Commission). SEC finds these allegations to be true as to company and revokes the registration of each class of their registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.

SEC Orders Hearing On Registration Suspension Or Revocation Against HemoBioTech

In conjunction with trading suspension, the Securities and Exchange Commission (SEC) also instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of HemoBioTech, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
Pinpoint Genomics, Inc. United States
Mountain View Pharmaceuticals, Inc. United States
Direct Pharmaceutical United States
Upstate Group, Inc. United States
AeroGenics, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hemobiotech, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at